Accelerating Scientific Decisions™

to reduce time, cost, and risk associated with the drug discovery process

almost **90%** of candidate drugs fail in the first stage of clinical trials, meaning that most trial drugs that passed preclinical testing will never be tested on humans.[1]

ONLY **250** out of **10,000** experimental compounds move past preclinical research[2]

Meaning, the likelihood that an experimental compound will move forward is a mere **.0250%**[3]

THE FDA APPROVED **ONLY 55** new drugs in 2018[3]

COST IS RISING FOR DEVELOPMENT

1 MEDICINE COSTS an average of **2.6 billion**[5]

CURRENTLY there are about **7,000 medicines** in clinical development globally

and

74% have the potential to be first-in-class treatments[4]— but need to make it through preclinical research first

75+ drugs in development for NASH

250+ drugs in development for obesity

200+ drugs in development for cardiovascular disease & stroke

To get organizations to the next phase of drug discovery faster or to prevent unnecessary and costly steps forward,

what options do lab directors have?

Reduce the time, cost, and risk associated with the drug discovery process

by using nuclear receptor and *in vitro* toxicology solutions from INDIGO.

13+ years of empowering lab directors to make confident decisions about their compounds

OUR SOLUTIONS

- **Nuclear Receptor Assay Kits**
- **Research & Screening Services**
- **Live Cell Multiplex**
- ***In Vitro* Hepatotoxicity Platform**
- **Gene Expression**
- **Nuclear Receptor Profiling**

HERE'S HOW

1. Largest portfolio of cell-based nuclear receptor assays in the world to help you identify compounds with the highest sensitivity and the lowest potential for unwanted effects and off-target responses
2. Our kits deliver results in just 24 hours and provide the most comprehensive data for your investment
3. Hepatotoxicity is one of the major reasons that drugs can get rejected, and INDIGO has access to optimized human-derived liver cells for *in vitro* testing

5,000+ kits provided*

1,500+ compounds screened*

20+ countries served*

Our luminescence-based method and proprietary CryoMite™ preservation process = reproducible results lot to lot about the efficacy, potency, and selectivity of your compounds plus comprehensive lab reports that include helpful graphics, summaries, and insights.

Top 5 Markets Served

- Pharma-Biotech
- Academic
- CROs-Drug Discovery
- Environmental
- Chemical

Why labs choose and trust INDIGO

- Largest Portfolio of Nuclear Receptor Assays
- Clear, Reproducible Nuclear Receptor and *In Vitro* Toxicology Results
- Team Committed to Your Study's Success
- Fast Lab Results for Accelerated Decision-Making
- Reliable Science, Platforms, & People

For more information, visit **indigobiosciences.com**

Sources

1. https://www.oxfordmartin.ox.ac.uk/downloads/academic/Transforming_Drug_Discovery.pdf
2. https://cpb-us-e1.wpmucdn.com/sites.northwestern.edu/dist/8/665/files/2015/10/Drug_RD_Brochure-12e7vs6.pdf
3. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm592464.htm
4. http://phrma.org/industryprofile/2018/
5. https://catalyst.phrma.org/developing-a-new-drug-is-actually-harder-than-rocket-science

* In past three years

INDIGO BIOSCIENCES

Nuclear Receptor & *In Vitro* Toxicology Solutions™